The synthesis and SAR of novel diarylsulfone 11beta-HSD1 inhibitors
Yan, X., Wang, Z., Sudom, A., Cardozo, M., DeGraffenreid, M., Di, Y., Fan, P., He, X., Jaen, J.C., Labelle, M., Liu, J., Ma, J., McMinn, D., Miao, S., Sun, D., Tang, L., Tu, H., Ursu, S., Walker, N., Ye, Q., Powers, J.P.(2010) Bioorg Med Chem Lett 20: 7071-7075
- PubMed: 20971000 
- DOI: https://doi.org/10.1016/j.bmcl.2010.09.097
- Primary Citation of Related Structures:  
3OQ1 - PubMed Abstract: 
In this communication, human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitory activities of a novel series of diarylsulfones are described. Optimization of this series resulted in several highly potent 11β-HSD1 inhibitors with excellent pharmacokinetic (PK) properties. Compound (S)-25 showed excellent efficacy in a non-human primate ex vivo pharmacodynamic model.
Organizational Affiliation: 
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. xueleiy@amgen.com